Early Detection of Cerebral Glucose Uptake Changes in the 5XFAD Mouse
Brain glucose hypometabolism has been observed in Alzheimer’s disease (AD) patients, and is detected with
18F radiolabelled glucose, using positron emission tomography. A pathological hallmark of AD is deposition of brain β-
amyloid plaques that may influence cerebral glucose metabolism. The five times familial AD (5XFAD) mouse is a model
of brain amyloidosis exhibiting AD-like phenotypes. This study examines brain β-amyloid plaque deposition and 18FDG
uptake, to search for an early biomarker distinguishing 5XFAD from wild-type mice. Thus, brain 18FDG uptake and
plaque deposition was studied in these mice at age 2, 5 and 13 months. The 5XFAD mice demonstrated significantly reduced
brain 18FDG uptake at 13 months relative to wild-type controls but not in younger mice, despite substantial β-
amyloid plaque deposition. However, by comparing the ratio of uptake values for glucose in different regions in the same
brain, 5XFAD mice could be distinguished from controls at age 2 months. This method of measuring altered glucose metabolism
may represent an early biomarker for the progression of amyloid deposition in the brain. We conclude that brain
18FDG uptake can be a sensitive biomarker for early detection of abnormal metabolism in the 5XFAD mouse when alternative
relative uptake values are utilized.
Keywords: Alzheimer's disease, β-amyloid, computed tomography, glucose metabolism, magnetic resonance imaging, positron
emission tomography, standardized uptake value, Tg6799.
Rights & PermissionsPrintExport